Abstracts tagged "giant cell arteritis"

Abstract Number: 1210 • 2019 ACR/ARP Annual Meeting
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Arash Hassantoufighi ¹, Rachel Lu-Do¹, Mamta Sherchan ¹, Christopher Collins ¹, Joshpaul Dhillon ² and Florina Constantinescu ¹, ¹MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ²MedStar Washington Hospital Center, Department of Internal Medicine, Washington, DC
Background/Purpose: Giant Cell Arteritis (GCA) is an autoimmune vasculitis, most common in older adults with a peak incidence in the seventh decade. The diagnosis is…
Abstract Number: 2661 • 2019 ACR/ARP Annual Meeting
A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. The historical gold standard for diagnosis is a…
Abstract Number: 2686 • 2019 ACR/ARP Annual Meeting
Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry
Shirish Dubey¹, Jonathan Pinnell ², Carl Tiivas ¹, Kaushik Chaudhuri ¹ and Purnima Mehta ¹, ¹University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²University Hospital North Staffordshire NHS Trust, Stoke, United Kingdom
Background/Purpose: University Hospital Coventry and Warwickshire NHS Trust (UHCW) established its one stop Fast Track Pathway (FTP) for Giant Cell Arteritis (GCA) in 2013. It…
Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
Abstract Number: 2662 • 2019 ACR/ARP Annual Meeting
Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?
Raymond Chu¹, Caylea Foster ², Mohsin Ali ³, Todd Chaba ¹, Jason Soo ¹, Alison Clifford ¹, Jan Willem Cohen Tervaert ¹ and Elaine Yacyshyn ¹, ¹University of Alberta, Edmonton, Canada, ²University of Calgary, Calgary, Canada, ³Harvard, Boston, MA
Background/Purpose: Temporal arteritis or giant cell arteritis (GCA) is a large vessel vasculitis that involves extracranial arteries. Diagnosis requires a combination of clinical manifestations including…
Abstract Number: 2687 • 2019 ACR/ARP Annual Meeting
Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis
Michael Putman¹, K Bates Gribbons ², Anthea Craven ³, Cristina Ponte ⁴, Joanna Robson ⁵, Ravi Suppiah ⁶, Richard Watts ⁷, Raashid Luqmani ³, Peter Merkel ⁸, Amy Archer ⁹ and Peter C. Grayson ¹⁰, ¹Northwestern University, Chicago, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ⁵Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁶Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁷Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁸University of Pennsylvania, Pennsylvania, ⁹Northwestern, Chicago, ¹⁰National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: In addition to aiding in diagnosis, histopathologic findings from temporal artery biopsy (TAB) specimens in giant cell arteritis (GCA) may be valuable for their…
Abstract Number: 1837 • 2019 ACR/ARP Annual Meeting
Ustekinumab for the Treatment of Giant Cell Arteritis
Mark Matza¹, John Stone ¹, Ana Fernandes ¹ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Disease flare despite high cumulative glucocorticoid exposure is one of the hallmarks of giant cell arteritis (GCA). Tocilizumab is effective in controlling disease activity…
Abstract Number: 2664 • 2019 ACR/ARP Annual Meeting
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Jean-Paul Makhzoum¹, Meriem Belhocine ¹, Michelle Goulet ¹, Maxime Rheaume ¹, Tara Starnino ², Stephanie Ducharme-Benard ², Guillaume Febrer ³, Yves Troyanov ⁴, Nathalie Routhier ⁵, Rosalie-Selene Meunier ⁵, Isabelle Chagnon ⁵, Michel Laurier ⁵, Maggy Helou ⁵, Nathalie Morency ⁶ and Anne-Marie Mansour ¹, ¹Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ³Vascular Surgery, Department of Surgery, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁴Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁵Internal Medicine, Department of Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada, ⁶Division of Rheumatology, Department of Medicine, Montreal, Canada
Background/Purpose: Giant Cell Arteritis (GCA) remains challenging to diagnose as false negative temporal artery biopsy (TAB) can occur. Color doppler ultrasonography (CDUS) of the temporal,…
Abstract Number: 2688 • 2019 ACR/ARP Annual Meeting
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Raashid Luqmani ³, Richard Watts ⁶, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Diagnostic assessment in giant cell arteritis (GCA) is rapidly changing as large-vessel (LV) involvement becomes increasingly recognized and non-invasive vascular imaging techniques become more…
Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Hubert de BOYSSON¹, Eric LIOZON ², Olivier ESPITIA ³, Aurélie DAUMAS ⁴, Mathieu VAUTIER ⁵, Marc LAMBERT ⁶, Jean-Jacques PARIENTI ⁷, Alain MANRIQUE ⁷, David Saadoun ⁸, Kim Heang Ly ², Christian Agard ⁹ and Achille Aouba ¹⁰, ¹University Hospital of Caen, Caen, France, ²Limoges University Hospital, Limoges, France, ³Nantes University Hospital, Nantes, France, ⁴Marseille AP-HM, Marseille, France, ⁵Paris - Pitié salpétrière, Paris, France, ⁶Lille University Hospital, Lille, France, ⁷Caen University Hospital, Caen, France, ⁸AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁹CHU Nantes, Nantes, France, ¹⁰CHU Caen, Caen, France
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Ingeborg Sacksen ¹, Elizabeth Jernberg ¹, Scott Pollock ², Jean Liew ³, Sarah Chung ², R Eugene Zierler ³ and Alison Bays², ¹University of Washington Division of Rheumatology, Seattle, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may result in visual impairment. Although the gold…
Abstract Number: 1841 • 2019 ACR/ARP Annual Meeting
Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study
Verena Schönau ¹, Jessica Roth ¹, Koray Tascilar ², Jürgen Rech ³, Daniela Schmidt ⁴, Torsten Kuwert ⁴, Filippo Crescentini ⁵, Luigi Boiardi ⁶, Massimiliano Casali ⁷, Annibale Versari ⁸, Giulia Pazzola ⁵, Georg Schett ⁹, Carlo Salvarani ¹⁰ and Francesco Muratore¹¹, ¹Rheumatology Unit, University of Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Nuclear Medicine Unit, University of Erlangen, Erlangen, Germany, ⁵Rheumatology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁶Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁷Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁸Nuclear Medicine Unit, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, ⁹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: 18F-FDG-PET/CT is a sensitive and comprehensive technique to diagnose giant cell arteritis (GCA). This technique may be also very useful to test whether vascular…
Abstract Number: 2669 • 2019 ACR/ARP Annual Meeting
Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Thomas Garvey¹, Cynthia Crowson ¹, Matthew Koster ², Eric Matteson ³ and Kenneth Warrington ², ¹Mayo Clinic Rochester, Rochester, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: To investigate survival trends in patients with giant cell arteritis (GCA) diagnosed over a 60-year period.Methods: We assembled a population-based incidence cohort of patients…
Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].